BOSTON, Aug. 21, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today reported its financial results for the second quarter and six months ended June 30, 2017 and provided a business update.
“The Phase 3 clinical program for A4250, our promising IBAT inhibitor for the treatment of children with progressive familial intrahepatic cholestasis (PFIC), is planned to commence by the end of 2017. This program is an important step towards our goal of providing a new, non-surgical treatment for children afflicted with this life-altering disease,” said Ron Cooper, President and Chief Executive Officer of Albireo. “As we proceed with our Phase 3 plans for A4250, we were pleased to strengthen our balance sheet in the second quarter with the completion of an equity offering that resulted in approximately $48.5 million in new capital for Albireo.”
